PMID: 8942881Nov 1, 1996Paper

Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group

Ophthalmology
R A HyndiukV Klauss

Abstract

The purpose of the study is to compare the clinical efficacy and safety of ciprofloxacin ophthalmic solution 0.3% (Ciloxan) with a standard therapy regimen (fortified tobramycin, 1.3%-cefazolin, 5.0%) for treating bacterial corneal ulcers. This randomized, parallel group, double-masked, multicenter study was conducted in 324 patients at 28 centers in the United States, Europe, and India. Patients were randomized into 2 treatment groups: 160 to ciprofloxacin and 164 to fortified tobramycin-cefazolin. Positive microbiologic cultures were obtained in 188 (58%) of 324 patients. Of these, 176 patients met protocol criteria and were evaluated for treatment efficacy: 82 in the ciprofloxacin group and 94 in the standard therapy group. The dosing schedule for both treatment groups was 1 to 2 drops of the first study medication (ciprofloxacin or fortified tobramycin) every 30 minutes for 6 hours, then hourly for the remainder of day 1; 1 to 2 drops every hour on days 2 and 3; 1 to 2 drops every 2 hours on days 4 and 5, followed by 1 to 2 drops every 4 hours on days 6 to 14. The second medication (ciprofloxacin or cefazolin) was instilled 5 to 15 minutes after the first drug, following the same dosing frequency. Physician's judgment of cl...Continue Reading

References

Jan 1, 1973·International Ophthalmology Clinics·J L BaumL Weinstein
Feb 1, 1983·Ophthalmology·J Baum, M Barza
Aug 24, 1995·The New England Journal of Medicine·J HofmannR F Breiman
Nov 1, 1994·Cornea·M Limberg, C Buggé

❮ Previous
Next ❯

Citations

Jan 12, 2007·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·W Behrens-Baumann, U Pleyer
Dec 4, 2003·American Journal of Ophthalmology·Kirk R Wilhelmus, Robert L Abshire
Jul 16, 1999·Ophthalmology·M H GoldsteinY J Gordon
Jul 16, 1999·Ophthalmology·P GargG N Rao
Oct 16, 1999·Ophthalmology·H R Katz
Jun 27, 2007·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Ping BuCharles S Bouchard
Mar 26, 2010·Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics·Melissa E SandersMary E Marquart
Jan 1, 2004·Cornea·Kirk R Wilhelmus, Barry A Schlech
Oct 25, 2006·International Ophthalmology Clinics·Stephen D McLeod
Nov 26, 2010·Cornea·María Alejandra Carrasco, Graciela Genesoni
Jun 11, 2010·Indian Journal of Ophthalmology·Sujata DasAparajita Mallick
Nov 1, 2001·Journal of Cataract and Refractive Surgery·R A EifermanR E Nordquist
Mar 24, 2000·The British Journal of Ophthalmology·N GangopadhyayH R Taylor
Jun 30, 2000·The British Journal of Ophthalmology·S J Tuft, M Matheson
Jun 26, 2001·The British Journal of Ophthalmology·F SchaeferY Guex-Crosier
Jun 19, 2003·The British Journal of Ophthalmology·B H Jeng, S D McLeod
Aug 21, 2003·The British Journal of Ophthalmology·T WongC N J McGhee
Aug 21, 2003·The British Journal of Ophthalmology·M Daniell
Apr 19, 2005·The British Journal of Ophthalmology·T K H ButlerK McClellan
Jun 29, 2007·The British Journal of Ophthalmology·Faiz Al-Shakarchi
Apr 18, 2008·Indian Journal of Ophthalmology·Nikhil S Gokhale
Oct 3, 2008·The British Journal of Ophthalmology·M SrinivasanN R Acharya
Mar 1, 2012·Cornea·Barbara A Brown-ElliottRichard J Wallace
Jul 15, 2015·Ocular Immunology and Inflammation·Massimo AccorintiFrancesca Romana Pesci
Mar 15, 2006·Current Eye Research·Clare C McCormickRichard J O'Callaghan
Dec 12, 2012·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Marie-Sophie HanetAlessandra Pinheiro Chaves
Nov 29, 2011·Survey of Ophthalmology·Vishal JhanjiRasik B Vajpayee
Mar 15, 2011·Survey of Ophthalmology·Neelakshi BhagatMarco Zarbin
Feb 2, 2011·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Jason BlairAllan Slomovic
Oct 29, 2015·Cornea·Lamprini PapaioannouMiltiadis Papathanassiou

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.